Home Cart Sign in  
Chemical Structure| 1095004-78-6 Chemical Structure| 1095004-78-6

Structure of AZD7624
CAS No.: 1095004-78-6

Chemical Structure| 1095004-78-6

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

AZD7624 is an inhalable p38 inhibitor with potent anti-inflammatory activity.

Synonyms: AZD7624

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of AZD7624

CAS No. :1095004-78-6
Formula : C27H30FN5O3
M.W : 491.56
SMILES Code : O=C(NC1CC1)C2=CC(N3C(C(NC4(C5=CC=CC=C5OCCNC)CC4)=NC=C3)=O)=C(C)C(F)=C2
Synonyms :
AZD7624
MDL No. :MFCD30488989

Safety of AZD7624

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319-H335
Precautionary Statements:P261-P305+P351+P338

Related Pathways of AZD7624

MAPK
TLR

Isoform Comparison

Biological Activity

Clinical Trial:

NCT Number Conditions Phases Recruitment Completion Date Locations
NCT01817855 COPD Healthy ... More >>Subjects Less << Phase 1 Completed - United Kingdom ... More >> Research Site London, United Kingdom Less <<
NCT02238483 Chronic Obstructive Pulmonary ... More >>Disease COPD Less << Phase 2 Completed - -
NCT02753764 Corticosteroid Resistant (CR) ... More >>Asthmatics Less << Phase 2 Recruiting January 2018 United States, Colorado ... More >> National Jewish Health Recruiting Denver, Colorado, United States, 80206 Sub-Investigator: Elena Goleva, PhD          Principal Investigator: Donald Leung, MD, PhD Less <<
NCT01754844 Chronic Obstructive Pulmonary ... More >>Disease (COPD) Less << Phase 1 Completed - United Kingdom ... More >> Research Site London, United Kingdom Less <<
NCT01817855 - Completed - -
NCT02238483 - Completed - -
NCT01937338 LPS Challenge, Neutrophils Phase 1 Completed - United Kingdom ... More >> Research Site London, United Kingdom Less <<

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

2.03mL

0.41mL

0.20mL

10.17mL

2.03mL

1.02mL

20.34mL

4.07mL

2.03mL

Dissolving Methods
Please choose the appropriate dissolution scheme according to your animal administration guide.For the following dissolution schemes, clear stock solution should be prepared according to in vitro experiments, and then cosolvent should be added in turn:

in order to ensure the reliability of the experimental results, the clarified stock solution can be properly preserved according to the storage conditions; The working fluid for in vivo experiment is recommended to be prepared now and used on the same day;

The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1
Protocol 2
 

Historical Records

Categories